ConductScience.org, home

Paper30901302

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A and 30 others. J Clin Oncol, 2019. Cited by 516 papers, by iCite.

Cite this record

ConductScience Library. Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma. Papers, record 30901302. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/30901302

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.
PubMed
Journal
J Clin Oncol
PubMed
Year
2019
PubMed
Publication types
Clinical Trial, Phase III, Journal Article, Randomized Controlled Trial, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
516
iCite
Relative citation ratio, by iCite
18.5
iCite
Revised in PubMed
2022-04-10
PubMed

Authors31

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Younes AAnas
2Sehn LHLaurie H
3Johnson PPeter
4Zinzani PLPier Luigi
5Hong XXiaonan
6Zhu JJun
7Patti CCaterina
8Belada DDavid
9Samoilova OOlga
10Suh CCheolwon
11Leppä SSirpa
12Rai SShinya
13Turgut MMehmet
14Jurczak WWojciech
15Cheung MCMatthew C
16Gurion RRonit
17Yeh SPSu-Peng
18Lopez-Hernandez AAndres
19Dührsen UUlrich
20Thieblemont CCatherine

Source PubMed

See all 31 authorsDownload CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Lymphoma, Large B-Cell, DiffuseMajor topic
Adenine
Adult
Aged
Aged, 80 and over
Cyclophosphamide
Double-Blind Method
Doxorubicin
Female
Humans
Kaplan-Meier Estimate
Male
Middle Aged
Piperidines
Placebos
Prednisone
Progression-Free Survival
Pyrazoles
Pyrimidines
Rituximab
Survival Rate
Vincristine
Young Adult

Source PubMed

Download CSV of topics

Grants2

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
P30 CA008748NCI NIH HHSUnited StatesP30CA008748PubMed and NIHNIH RePORTER
ZIABC011354NIHNIH RePORTER

Download CSV of grants

Trials2

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's recordSource
NCT01855750
A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
Derived from the trialYesClinicalTrials.gov
NCT06251180Phase Ib Study of Rocbrutinib in Combination With R-CHOP in Patients With Newly Diagnosed B-cell Non-Hodgkin LymphomaResultsClinicalTrials.gov

Download CSV of trials

Comments and corrections3

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn PapersSource
Comment in30945958De-Cell-eration in Therapy for Diffuse Large B-Cell Lymphoma.https://conductscience.org/library/papers/30945958PubMed
Comment in31390273Reply to M. Skelin et al.https://conductscience.org/library/papers/31390273PubMed
Comment in31390275Above What Age Should Ibrutinib Not Be Given With R-CHOP to Patients With Non-GBC DLBCL?https://conductscience.org/library/papers/31390275PubMed

Download CSV of comments and corrections

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
110676951Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.Nature2000https://conductscience.org/library/papers/10676951PubMed
211160144Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.J Clin Invest2001https://conductscience.org/library/papers/11160144PubMed
314504078Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood2004https://conductscience.org/library/papers/14504078PubMed
417242396Revised response criteria for malignant lymphoma.J Clin Oncol2007https://conductscience.org/library/papers/17242396PubMed
517266164A method for testing a prespecified subgroup in clinical trials.Stat Med2007https://conductscience.org/library/papers/17266164PubMed
623339126Diffuse large B-cell lymphoma in the elderly: a review of potential difficulties.Clin Cancer Res2013https://conductscience.org/library/papers/23339126PubMed
723454758Causes, consequences, and reversal of immune system aging.J Clin Invest2013https://conductscience.org/library/papers/23454758PubMed
824398326Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue.Blood2014https://conductscience.org/library/papers/24398326PubMed
925042202
Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Lancet Oncol2014https://conductscience.org/library/papers/25042202PubMed
1025342313Treatment patterns and comparative effectiveness in elderly diffuse large B-cell lymphoma patients: a surveillance, epidemiology, and end results-medicare analysis.Oncologist2014https://conductscience.org/library/papers/25342313PubMed
1125488930Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.Drug Metab Dispos2015https://conductscience.org/library/papers/25488930PubMed
1225884669A longitudinal study of non-medical determinants of adherence to R-CHOP therapy for diffuse large B-cell lymphoma: implication for survival.BMC Cancer2015https://conductscience.org/library/papers/25884669PubMed
1326193343Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.Nat Med2015https://conductscience.org/library/papers/26193343PubMed
1426314773Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.Ann Oncol2015https://conductscience.org/library/papers/26314773PubMed
1527089170ROBUST: Lenalidomide-R-CHOP versus placebo-R-CHOP in previously untreated ABC-type diffuse large B-cell lymphoma.Future Oncol2016https://conductscience.org/library/papers/27089170PubMed
1628426350
Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.
J Clin Oncol2017https://conductscience.org/library/papers/28426350PubMed
1728751558Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.Haematologica2017https://conductscience.org/library/papers/28751558PubMed
1828796588Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma.J Clin Oncol2017https://conductscience.org/library/papers/28796588PubMed
1929641966Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma.N Engl J Med2018https://conductscience.org/library/papers/29641966PubMed
2029672223Diagnosis-to-Treatment Interval Is an Important Clinical Factor in Newly Diagnosed Diffuse Large B-Cell Lymphoma and Has Implication for Bias in Clinical Trials.J Clin Oncol2018https://conductscience.org/library/papers/29672223PubMed

See all 21 referencesDownload CSV of references

Cited by340

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 516 citations.

PMIDTitleJournalYearIn PapersSource
42972012The cyclin-G associated kinase (GAK) is a clinically actionable drug target required for mitosis in diffuse large B-cell lymphoma.Leukemia2026https://conductscience.org/library/papers/42972012PubMed
42827714Bruton's Tyrosine Kinase Inhibitors: Mechanisms, Efficacy, Toxicities and Applications for the Treatment of Human Diseases.MedComm (2020)2026https://conductscience.org/library/papers/42827714PubMed
42636799Cell-free DNA genomic and fragmentomic features for early outcome prediction in large B cell lymphoma.Cell Rep Med2026https://conductscience.org/library/papers/42636799PubMed
42608144Glofitamab in combination with immunochemotherapy in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Phase 1b dose-escalation study.Br J Haematol2026https://conductscience.org/library/papers/42608144PubMed
42571242Alternative oncogenic drivers and sensitivity to BTK inhibition in CRISPR/Cas gene-edited human DLBCL cell models.Blood Neoplasia2026https://conductscience.org/library/papers/42571242PubMed
42500562Transcriptomic Study of Diffuse Large B-Cell Lymphoma Associated with HIV Infection: Identification of Novel Molecular Subtypes.Oncol Res2026https://conductscience.org/library/papers/42500562PubMed
42487683Molecular Pathogenesis and Therapeutic Response of Diffuse Large B Cell Lymphoma Genetic Subtypes.Annu Rev Cancer Biol2026https://conductscience.org/library/papers/42487683PubMed
42439665Diffuse Large B-Cell Lymphoma: From Molecular Stratification to Precision Immunotherapy.Cells2026https://conductscience.org/library/papers/42439665PubMed
42426809R-MINE-containing regimen in relapsed and refractory diffuse large B-cell lymphoma: a single-arm, multicenter phase II study.BMC Med2026https://conductscience.org/library/papers/42426809PubMed
42403594A Critical Review of PET/CT Assessment After CAR-T Cell Therapy in Large B-Cell Lymphoma, Limitations of Current Criteria, Emerging Biomarkers, and a Framework for Standardised Evaluation.J Multidiscip Healthc2026https://conductscience.org/library/papers/42403594PubMed
42386710Zanubrutinib combined with R-CHOP in previously untreated diffuse large B-cell lymphoma with specific gene alteration: a phase II study.Blood Cancer J2026https://conductscience.org/library/papers/42386710PubMed
42377894A case study of proteomics-guided personalized targeted therapy.Sci China Life Sci2026https://conductscience.org/library/papers/42377894PubMed
42369727Management of diffuse large B‑cell lymphoma in older adults: current strategies and emerging directions.Ther Adv Med Oncol2026https://conductscience.org/library/papers/42369727PubMed
42362499Pola-R-CHP as frontline therapy for diffuse large B-cell lymphoma: a systematic review and meta-analysis of randomized trials and real-world evidence.Blood Cancer J2026https://conductscience.org/library/papers/42362499PubMed
42295240Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models.Mol Cancer Ther2026https://conductscience.org/library/papers/42295240PubMed
42286378Emerging treatment strategies for newly diagnosed diffuse large B-cell lymphoma.Int J Clin Oncol2026https://conductscience.org/library/papers/42286378PubMed
42175874Response to: "Refining Combined-Modality Therapy and Charting the Future of Primary Vitreoretinal Lymphoma".Am J Hematol2026https://conductscience.org/library/papers/42175874PubMed
42172280Comparison of dose-adjusted EPOCH-R and R-CHOP in diffuse large B-cell lymphoma with high Ki67 expression: Results from a prospective observational study.PLoS One2026https://conductscience.org/library/papers/42172280PubMed
42151585Zanubrutinib potentiates polatuzumab vedotin efficacy in DLBCL with concurrent CD79b upregulation.Ann Hematol2026https://conductscience.org/library/papers/42151585PubMed
42074785Molecularly Adapted Antitumor Therapy for Newly Diagnosed Diffuse Large B-Cell Lymphoma: Two-Year Follow-Up Results.J Clin Med2026https://conductscience.org/library/papers/42074785PubMed

See all 340 cited byDownload CSV of cited by

Drugs7

The drugs whose trials, in the Pipelines release, list the paper.

DrugChEMBL IDThe trials list it asTrialsIn Drugs and targetsSource
CYCLOPHOSPHAMIDECHEMBL1200796Results2https://conductscience.org/library/drugs/CHEMBL1200796ChEMBL
RITUXIMABCHEMBL1201576Results2https://conductscience.org/library/drugs/CHEMBL1201576ChEMBL
IBRUTINIBCHEMBL1873475Derived from the trial1https://conductscience.org/library/drugs/CHEMBL1873475ChEMBL
ROCBRUTINIBCHEMBL5314539Results1https://conductscience.org/library/drugs/CHEMBL5314539ChEMBL
DOXORUBICINCHEMBL53463Results2https://conductscience.org/library/drugs/CHEMBL53463ChEMBL
PREDNISONECHEMBL635Results2https://conductscience.org/library/drugs/CHEMBL635ChEMBL
VINCRISTINECHEMBL90555Results2https://conductscience.org/library/drugs/CHEMBL90555ChEMBL

Download CSV of drugs

Data1

The data bank entries PubMed's record names. Trial numbers are under Trials.

Data bankAccession
EudraCT2013-000959-40

Source PubMed

Download CSV of data

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Genes

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/30901302

GET https://conductscience.org/api/papers/v1/30901302/authors?page=2